Group 1 - The innovative drug sector experienced a decline in early trading on June 18 [1] - The Tianhong Innovative Drug ETF (517380) saw a slight drop of 0.15% with a premium rate of 0.37%, indicating frequent premium trading [2] - Among the constituent stocks, Xiansheng Pharmaceutical rose over 2%, while Huabei Pharmaceutical and Zhaoyan New Drug fell over 3% [3] Group 2 - Despite a pullback since June 13, the Tianhong Innovative Drug ETF has seen a net inflow of over 30 million yuan in the last three trading days [3] - The ETF's circulating shares reached a new high of 724 million as of June 17, an increase of 20 million from the previous day [3] - The Tianhong Innovative Drug ETF is the largest in the market, covering both A-shares and Hong Kong stocks, and aims for superior risk-return characteristics [3] Group 3 - Industrial outlook for the innovative drug sector remains positive, driven by "innovation + internationalization" trends [4] - There is ongoing policy support and strengthening global competitiveness, with commercial profitability beginning to materialize [4] - The demand in the domestic market is expected to recover by 2025, particularly in the consumption medical sector [4]
回调下连续3日获资金净流入，创新药ETF天弘（517380）最新份额再创新高，机构：创新药板块景气度可持续
Sou Hu Cai Jing·2025-06-18 02:32